ChargePoint Technology and STERIS collaborate to bring sterile solutions for Evonik
.png)
Evonik will be provided with sterile solutions from a collaboration between ChargePoint Technology Group and STERIS, utilising ChargePoint’s AseptiSafe Bio Valve and STERIS’ bio-decontamination systems.
Powder and liquid transfer specialists ChargePoint Technology Group (Liverpool, UK) have partnered with STERIS (Mentor, USA), providers of infection prevention and other procedural products and services, to bring a successful sterile solution to chemicals company Evonik (Essen, Germany).
At its plant in Alabama, USA, Evonik manufactures complex parenteral medications using fill-finish lines handling a broad mix of products. Evonik will be utilising ChargePoint’s AseptiSafe® Bio Valve, which will be coupled to the STERIS Vaporised Hydrogen Peroxide bio-decontamination system. Optimised for continuous filling, the line will allow chemical products to move through processes rapidly and efficiently. Product transfer from a container to filling equipment maintained in a sterile environment will also be achieved through the solution. In addition, the ChargePoint AseptiSafe Split Butterfly Valve will securely connect the product and the container, further protecting sterility and the integrity of the API.
CEO of ChargePoint Technology Chris Eccles commented: “With the development of specialised medicines increasing, many manufacturers like Evonik have struggled to find specialised equipment that meet their requirements. It was absolutely crucial that Evonik could aseptically connect and disconnect the product vessel quickly to maintain product sterility. After reviewing multiple vendors, our system was found to provide the highest degree of product protection.”
The VHP 1000ED bio-decontamination unit from STERIS possesses the ability to decontaminate its surroundings and adapts easily to the manufacturing environment. By combining the abilities of ChargePoint and STERIS’ technologies, replacing product containers during manufacturing can occur aseptically within 1 hour while enabling continuous filling, further minimising downtime.
Caroline Hand, Production Engineer at Evonik, stated: “Evonik has been delighted by the results produced the multifaceted approach from ChargePoint and STERIS This partnership provided a solution that delivered the highest integrity when performing high volume aseptic product transfer with multiple product containers and significantly reduced the turnaround time of this project. We are thrilled with the outcomes.”
Associate Product Manager Abby Lovell from STERIS added: “Our continued partnership with ChargePoint means that its unique aseptic SBV technology in conjunction with STERIS’ VHP bio-decontamination system are collectively meeting the technical needs of the industry. This has allowed us to provide the ultimate sterile transfer solution to Evonik and we look forward to many more years of partnership.”
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance